FDA label
What is oseltamivir used for?
The FDA-approved uses of oseltamivir, quoted from the Indications and Usage section of its DailyMed label.
Source: DailyMed SPL label file dated 2026-10-23. Publisher page
The FDA label for oseltamivir phosphate (capsule) lists 2 uses: Treatment of Influenza; Prophylaxis of Influenza.
Run it in Rivvi
Which 2027 plans near you dropped or restricted oseltamivir?
Tier changes and new prior auth, step therapy or quantity limits, plan by plan.
Free to start. Opens Rivvi, the AI workspace for healthcare teams.
Oseltamivir Phosphate, capsule
Indications and Usage, quoted from the label by Sportpharm LLC (ANDA209438). Cross-references to other label sections are left out.
Treatment of Influenza
Oseltamivir phosphate capsules are indicated for the treatment of acute, uncomplicated illness due to influenza A and B infection in patients 2 weeks of age and older who have been symptomatic for no more than 48 hours.
Prophylaxis of Influenza
Oseltamivir phosphate capsules are indicated for the prophylaxis of influenza A and B in patients 1 year and older.
Limitations of Use
- Oseltamivir phosphate capsules are not a substitute for early influenza vaccination on an annual basis as recommended by the Centers for Disease Control and Prevention Advisory Committee on Immunization Practices. • Influenza viruses change over time. Emergence of resistance substitutions could decrease drug effectiveness. Other factors (for example, changes in viral virulence) might also diminish clinical benefit of antiviral drugs. Prescribers should consider available information on influenza drug susceptibility patterns and treatment effects when deciding whether to use oseltamivir phosphate capsules.
Source: DailyMed label, set id a8a40f98-f6bd-4ef0-af03-93ed0f473c10, version 2, effective April 24, 2026. NDC 85766-082, one of 94 listings for this product.
Oseltamivir Phosphate, powder, for suspension
Indications and Usage, quoted from the label by Teva Pharmaceuticals USA, Inc. (ANDA211125). Cross-references to other label sections are left out.
Treatment of Influenza
Oseltamivir phosphate for oral suspension is indicated for the treatment of acute, uncomplicated illness due to influenza A and B infection in patients 2 weeks of age and older who have been symptomatic for no more than 48 hours.
Prophylaxis of Influenza
Oseltamivir phosphate for oral suspension is indicated for the prophylaxis of influenza A and B in patients 1 year and older.
Limitations of Use
- Oseltamivir phosphate for oral suspension is not a substitute for early influenza vaccination on an annual basis as recommended by the Centers for Disease Control and Prevention Advisory Committee on Immunization Practices.
- Influenza viruses change over time. Emergence of resistance substitutions could decrease drug effectiveness. Other factors (for example, changes in viral virulence) might also diminish clinical benefit of antiviral drugs. Prescribers should consider available information on influenza drug susceptibility patterns and treatment effects when deciding whether to use oseltamivir phosphate for oral suspension.
- Oseltamivir phosphate for oral suspension is not recommended for patients with end-stage renal disease not undergoing dialysis.
Source: DailyMed label, set id 3ea5bf8f-c3fa-4d44-bc3d-b1912374ee4b, version 6, effective May 1, 2025. NDC 0093-8180, one of 14 listings for this product.
Oseltamivir Phosphate, for suspension
Indications and Usage, quoted from the label by Alembic Pharmaceuticals Inc. (ANDA218307). Cross-references to other label sections are left out.
Treatment of Influenza
Oseltamivir phosphate for oral suspension is indicated for the treatment of acute, uncomplicated illness due to influenza A and B infection in patients 2 weeks of age and older who have been symptomatic for no more than 48 hours.
Prophylaxis of Influenza
Oseltamivir phosphate for oral suspension is indicated for the prophylaxis of influenza A and B in patients 1 year and older.
Limitations of Use
- Oseltamivir phosphate for oral suspension is not a substitute for early influenza vaccination on an annual basis as recommended by the Centers for Disease Control and Prevention Advisory Committee on Immunization Practices. • Influenza viruses change over time. Emergence of resistance substitutions could decrease drug effectiveness. Other factors (for example, changes in viral virulence) might also diminish clinical benefit of antiviral drugs. Prescribers should consider available information on influenza drug susceptibility patterns and treatment effects when deciding whether to use oseltamivir phosphate for oral suspension.
Source: DailyMed label, set id 379f59fe-22d9-4bac-b9b5-31fdaebbd923, version 6, effective June 29, 2026. NDC 62332-769, one of 11 listings for this product.
Questions
What is oseltamivir used for?
The FDA label for oseltamivir phosphate (capsule) lists 2 uses: Treatment of Influenza; Prophylaxis of Influenza.
What drug class is oseltamivir?
FDA lists oseltamivir in the Neuraminidase Inhibitor established pharmacologic class.
Does this page cover off-label uses or dosing?
No. This page shows only the Indications and Usage section of the FDA label. Ask a pharmacist or prescriber about dosing.